Vaccines
Top executives from AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, and Sanofi have signed a historic pledge to ensure the safety and well-being of individuals vaccinated against COVID-19. The commitment comes as these companies work towards potential global regulatory filings and approvals of the first COVID-19 vaccines.
Pharmaceutical industry
CEOs of nine pharmaceutical companies, including AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, and Sanofi, have come together to issue a joint pledge reaffirming their commitment to developing and testing COVID-19 vaccines in accordance with high ethical standards and sound scientific principles. The CEOs acknowledge that regulatory
Pharmaceutical industry
The US economy is poised for further contraction, with forecasts indicating a 34.6% drop in second-quarter GDP. Meanwhile, major tech companies, including Apple, Amazon, and Facebook, are set to release earnings reports, which may influence investor sentiment. The Federal Reserve has pledged continued support for the economy, but its
Pharmaceutical industry
AstraZeneca's Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin. The Committee for Medicinal Products for Human Use
Pharmaceutical industry
US stocks erased early losses on Monday to close higher, fueled by tech giants' outperformance and positive COVID-19 vaccine trial results. The tech-heavy Nasdaq Composite notched a record high, while the S&P 500 reached its highest level since February. Tech mega-caps such as Apple, Microsoft, Netflix, and
Pharmaceutical industry
The stock market is facing a mixture of concerns and developments on Monday, July 20. Investors are turning their attention to a flurry of earnings reports, including those from IBM and Halliburton, while the situation with the coronavirus pandemic worsens, with the number of confirmed cases reaching 14,508,892
Pharmaceutical industry
The global GBM drugs market is expected to reach nearly $1.4 billion by 2025, expanding at a compound annual growth rate (CAGR) of 12.6% during the forecast period. This growth is driven by the rising geriatric population, growing incidence cases, and a rich clinical pipeline of new products.
Pharmaceutical industry
The global glioblastoma multiforme (GBM) drugs market is expected to experience significant growth, driven by a rising geriatric population, increasing incidence cases, and a rich clinical pipeline of new products. GBM is the most common primary malignant form of brain cancer, with an incidence of two to three per 100,
Pharmaceutical industry
The Drugs industry is experiencing a downturn, with all three major indices showing a decline. As of Friday, Dec. 18, 2015, at 11:55 AM ET, the Dow Jones Industrial Average is down 230 points, or 1.3%, at 17,266. The NYSE advances/declines ratio is 1,238 issues
Pharmaceutical industry
Thursday's Wall Street session saw stocks pivot toward the commodities market, indicating a shift in focus from the Federal Reserve's announcement of a rate hike. The S&P 500 declined 0.9%, the Dow Jones Industrial Average fell 0.76%, and the Nasdaq slid 0.
Pharmaceutical industry
The dramatic decline of Clovis Oncology on Monday bears a striking resemblance to the infamous ImClone Systems scandal of 2001. Clovis's decision to withhold information about the efficacy of its lung cancer drug, rociletinib, from investors until the FDA compelled the company to disclose the truth has sparked
Pharmaceutical industry
Clovis Oncology's struggle to bring its targeted lung cancer drug rociletinib to market has taken a significant hit as the US FDA has requested additional clinical data, delaying the approval review and putting Clovis further behind rival AstraZeneca. The FDA's decision is largely due to revised
